| ||
Faster Cures interviews SGC Director Aled Edward on their Innovators spotlight.
Aled Edwards: Carrying Out Open-Access Research in Structural and Chemical Biology
| ||
Faster Cures interviews SGC Director Aled Edward on their Innovators spotlight.
Aled Edwards: Carrying Out Open-Access Research in Structural and Chemical Biology
SGC Toronto will hold the “Histone methyltransferases; Structure, Mechanism and Inhibition” symposium in Toronto on Thursday August 21st, 2014. During this one-day epigenetics symposium ten renowned speakers will present their work on Protein Arginine Methyltransferases (PRMTs), Protein Lysine Methyltransferases (PKMTs) and related medicinal chemistry. This symposium is sponsored by ChemNet, an NSERC CREATE medicinal chemistry training programme in partnership with the SGC and the pharmaceutical industry.
For more details, please go to http://www.thesgc.org/symposia/toronto/MTase-2014
A news article in this week's Nature Medicine entitled "Patent-free pact pushes the boundaries of precompetitive research" highlights the work of the SGC's precompetitive public-private partnership model that requires an agreement to make all output freely available to the public without any restriction on use, such a the development of patents.
The Group led by Professor Chas Bountra, Chief Scientist of SGC Oxford, has been awarded the Royal Society of Chemistry's Rita and John Cornforth Award 2014 for "... world leading collaborative research across the disciplines of structural biology, medicinal chemistry, chemical biology and enzymology towards understanding and exploiting the potential of epigenetics as a target family for future drug discovery".
The Group led by Professor Chas Bountra, Chief Scientist of SGC Oxford, has been awarded the Royal Society of Chemistry's Rita and John Cornforth Award 2014 for "... world leading collaborative research across the disciplines of structural biology, medicinal chemistry, chemical biology and enzymology towards understanding and exploiting the potential of epigenetics as a target family for future drug discovery".
Inhibiting bromodomains - which are small interaction modules on proteins that assemble acetylation-dependent transcriptional regulatory complexes - could be a way to alter the expression of disease-promoting genes. In a Nature Reviews Drug Discovery article, the SGC highlights recent developments in the discovery of small-molecule bromodomain inhibitors and discuss how they might be used in cancer, inflammation and viral infection.